On August 13, 2024, the US Food and Drug Administration (FDA) approved nemolizumab for the treatment of adults with prurigo nodularis (PN). A first-in-class monoclonal antibody specifically designed to inhibit interleukin (IL)-31 signaling, nemolizumab, will be available in a pre-filled pen for subcutaneous injection and will be marketed as Nemluvio…
